"Having been involved with the creation of this new technology, I've seen first-hand the potential for it to radically change neurosurgical training and benefit patient care. I'm thrilled that with the purchase by UH our physicians and neurosurgery residents will benefit first from the innovation," said Dr. Selman, who is also Neurosurgeon-in-Chief at University Hospitals and the Harvey Huntington Brown Jr., Professor at Case Western Reserve University School of Medicine.
Surgical Theater launched the Platform at the Congress of Neurological Surgeons Annual Meeting in early October after receiving their first broad patent approval and submitting their application to the FDA.
"To have our first sale so quickly after launch, and with the forecast of more than five additional sales in coming months, is gratifying after so many months of hard work," said Avisar. "We're excited first and foremost at the potential for improved patient outcomes, and at the same time anticipate this sale is the beginning of great things for our company."
Peter R. Brumbergs Named CFO
Along with the initial sale and the patent approval, interest in the company has emerged from a number of investors. To help manage these investment opportunities as well as company finances, Surgical Theater recently named Peter R. Brumbergs as its first Chief Financial Officer. Brumbergs is a savvy business leader with more than 35 years of experience at Fortune 500, middle-market and entrepreneurial companies.
Most recently Brumbergs was CFO of U.S. Endoscopy, a medical device manufacturer with world-wide distribution, and was a member of the executive team that led and closed the sale of U.S. Endosc
|Contact: George Stamatis|
University Hospitals Case Medical Center